Evaluation of the antitumor effects of c-Myc-Max heterodimerization inhibitor 100258-F4 in ovarian cancer cells

@inproceedings{Wang2014EvaluationOT,
  title={Evaluation of the antitumor effects of c-Myc-Max heterodimerization inhibitor 100258-F4 in ovarian cancer cells},
  author={Jiandong Wang and Xiaoli Ma and Hannah M. Jones and Leo Li-Ying Chan and Fang Song and Weiyuan Zhang and Victoria L. Bae-Jump and Chunxiao Zhou},
  booktitle={Journal of Translational Medicine},
  year={2014}
}
Epithelial ovarian carcinoma is the most lethal gynecological cancer due to its silent onset and recurrence with resistance to chemotherapy. Overexpression of oncogene c-Myc is one of the most frequently encountered events present in ovarian carcinoma. Disrupting the function of c-Myc and its downstream target genes is a promising strategy for cancer therapy. Our objective was to evaluate the potential effects of small-molecule c-Myc inhibitor, 10058-F4, on ovarian carcinoma cells and the… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS
9 Citations
33 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 33 references

Effects of Coptis extract combined with chemotherapeutic agents on ROS production, multidrug Wang et al

  • C He, R Rong, J Liu, J Wan, K Zhou, JX Kang
  • Journal of Translational Medicine
  • 2014
1 Excerpt

Similar Papers

Loading similar papers…